{"id":92149,"date":"2022-12-05T00:00:00","date_gmt":"2022-12-05T00:00:00","guid":{"rendered":"http:\/\/medgoo.com\/index.php\/2022\/12\/05\/fda-no-useful-monoclonal-antibody-treatments-left-against-new-covid-19-variants\/"},"modified":"2022-12-06T23:33:06","modified_gmt":"2022-12-06T23:33:06","slug":"fda-no-useful-monoclonal-antibody-treatments-left-against-new-covid-19-variants","status":"publish","type":"post","link":"https:\/\/medgoo.com\/index.php\/2022\/12\/05\/fda-no-useful-monoclonal-antibody-treatments-left-against-new-covid-19-variants\/","title":{"rendered":"FDA: No Useful Monoclonal Antibody Treatments Left Against New COVID-19 Variants"},"content":{"rendered":"<h3>\n<p>Immunocompromised patients can still receive convalescent plasma<\/p>\n<\/h3>\n<p><b>By Physician\u2019s Briefing Staff HealthDay Reporter<\/b><\/p>\n<p><b><\/b><\/p>\n<p>MONDAY, Dec. 5, 2022 (HealthDay News) &#8212; The last of six COVID-19 monoclonal antibody treatments has lost its federal authorization because, like the others, it no longer works against the newest omicron subvariants.<\/p>\n<p>This last monoclonal antibody was bebtelovimab, delivered as a one-hour intravenous infusion. The U.S. Food and Drug Administration said in a <a href=\"https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-bebtelovimab-not-currently-authorized-any-us-region\" target=\"_blank\" rel=\"noopener\">statement<\/a> announcing the authorization withdrawal that the drug was &#8220;not expected to neutralize omicron subvariants BQ.1 and BQ.1.1.&#8221;<\/p>\n<p>Those subvariants are now responsible for nearly 62 percent of new infections in the United States, <a href=\"https:\/\/covid.cdc.gov\/covid-data-tracker\/#variant-proportions\" target=\"_blank\" rel=\"noopener\">according to<\/a> the U.S. Centers for Disease Control and Prevention. &#8220;The big problem is that monoclonal antibodies bind to a very small piece of the virus. As the virus changes, we are now in a position in which we lost them all because they don&#8217;t bind to the virus anymore,&#8221; Arturo Casadevall, M.D., a professor of medicine at the Johns Hopkins School of Medicine in Baltimore, told <em>NBC News<\/em>.<\/p>\n<p>Bebtelovimab had been recommended for certain patients taking immunosuppressants, including cancer or transplant recipients, because the antiviral pill Paxlovid can interact negatively with those drugs, <em>NBC News<\/em> reported. Paxlovid is still available as a treatment for others at high risk for severe COVID-19.<\/p>\n<p>Immunocompromised patients can still receive convalescent plasma. &#8220;It has thousands of different antibodies, so convalescent plasma has a lot of breadth that is not found in the monoclonals,&#8221; Casadevall explained.<\/p>\n<p>New monoclonal antibodies that are a better fit to new COVID-19 subvariants may still become available over time. The pharmaceutical company AstraZeneca is developing an antibody cocktail that could be ready by year&#8217;s end. And an Eli Lilly spokesman said the company is searching for and evaluating potential monoclonal antibodies, <em>NBC News<\/em> reported.<\/p>\n<p><a href=\"https:\/\/www.nbcnews.com\/health\/health-news\/coronavirus-variants-monoclonal-antibody-drugs-ineffective-rcna59797\" target=\"_blank\" rel=\"noopener\"><em>NBC News<\/em> Article<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2022 <a href=\"https:\/\/www.healthday.com\/\" target=\"_new\" rel=\"noopener\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Immunocompromised patients can still receive convalescent plasma<\/p>\n","protected":false},"author":6,"featured_media":92240,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[11],"class_list":["post-92149","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"_links":{"self":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/92149","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/comments?post=92149"}],"version-history":[{"count":1,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/92149\/revisions"}],"predecessor-version":[{"id":92239,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/92149\/revisions\/92239"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media\/92240"}],"wp:attachment":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media?parent=92149"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/categories?post=92149"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/tags?post=92149"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}